Neovii Pharmaceuticals AG Establishes Global Scientific Department
Neovii continues to strengthen its leadership team and capabilities with the appointment of Richard Sachse as Global Chief Scientific Officer. With the appointment of Dr. Sachse, Neovii has set up a Global Scientific Department which comprises all regulatory, medical, and development activities globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180703005142/en/
Neovii’s CEO Juergen Pohle commented: “By establishing a Global Scientific Department, Neovii makes another step forward to become a leading biopharmaceutical company in the transplantation segment.” He added: “We are very excited that Richard joins Neovii and will establish the new Global Scientific Department. His deep understanding and long-term experience in clinical development and regulatory activities, as well as his know-how and strong leadership skills, make him the right person to push this role forward and to drive the business into our next chapter.” Dr. Sachse will also join Neovii’s Global Leadership Team.
Dr. Sachse previously held the position of Senior Vice President, Chief Scientific Officer, and Chief Medical Officer at Æterna Zentaris. In this role Dr. Sachse succeeded in designing and completing development programs for FDA drug approval. He draws on more than 20 years of experience in the pharmaceutical industry not only at Æterna Zentaris, but also with Boehringer Ingelheim, UCB, Schwarz Biosciences, Peptor, and Bayer.
Richard Sachse pointed out: “I am excited to join Neovii and to build the new Global Scientific Department comprising regulatory, medical, and development activities. Driving Neovii to become a full-fledged pharmaceutical company is a challenging but rewarding task, and I am certain that my previous experience will highly benefit Neovii. I am enthusiastic to begin working with our in-licensing partners to provide better paths to key markets for the most innovative lines of treatments in transplantation and rare diseases.”
Neovii also appointed former Pfizer executive Alfred Doucette as Global CFO at the beginning of the year. Alfred Doucette has held several senior finance positions within Pfizer and was most recently the Commercial Director for Pfizer Consumer Healthcare for the SEE/CIS/Baltics/Greece & Cyprus, Israel and Turkey regions, bringing a huge wealth of experience in financial management.
Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies.
Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders.
Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Lexingtion MA, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.
For further information
For further information, please visit www.neovii.com .
For Neovii Pharmaceuticals AG
Daniela Suter, 0041 (0)44 455 84 25
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-RESMED-INC15.7.2019 22:07:07 CEST | Press release
ResMed Inc. Completes $500M Private Placement Debt Offering
SPEEDX15.7.2019 17:02:04 CEST | Press release
SpeeDx Receives Clearance from Health Canada for ResistancePlus® MG Test
TX-MOUSER-ELECTRONICS15.7.2019 16:57:04 CEST | Press release
Mouser Electronics Now Stocking Broad Portfolio of Xilinx Products
CA-RIMINI-STREET15.7.2019 15:02:08 CEST | Press release
Rimini Street Becomes Support Service Provider for Hyundai-Kia Motors’ Global Database Portfolio
MN-VÄRDE-PARTNERS15.7.2019 14:14:05 CEST | Press release
Värde Partners Appoints Co-CEO
BOEHRINGER-INGELHEIM15.7.2019 14:02:04 CEST | Press release
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom